Drug Profile
Research programme: fungal infection therapies - Aparna Biosciences
Latest Information Update: 28 Aug 2020
Price :
$50
*
At a glance
- Originator Aparna Biosciences
- Developer Aparna Biosciences; University of Maryland, College Park
- Class Monoclonal antibodies
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Aspergillosis; Candidiasis; Cryptococcosis
Highest Development Phases
- No development reported Aspergillosis; Candidiasis; Cryptococcosis
Most Recent Events
- 28 Aug 2020 No recent reports of development identified for research development in Aspergillosis in USA
- 28 Aug 2020 No recent reports of development identified for research development in Candidiasis in USA
- 28 Aug 2020 No recent reports of development identified for research development in Cryptococcosis in USA